EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LPA1 antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities

Jingyue Yan, Diana D Kang, Chang Wang, Xucheng Hou, Shi Du, Siyu Wang, Yonger Xue, Zhengwei Liu, Haoyuan Li, Yichen Zhong, Binbin Deng, David W McComb und 1 weitere

Nano Research · 2024-10 · 17 (10) · 9095-9102

DOI: 10.1007/s12274-024-6747-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Research, online erschienen am 27.06.2024. Verfasst von Jingyue Yan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activated fibroblasts are major mediators of pulmonary fibrosis. Fibroblasts are generally found in the connective tissue but upon activation can generate excess extracellular matrix (ECM) in the lung interstitial section. Therefore, fibroblasts are one of the most targeted cells for treating idiopathic pulmonary fibrosis (IPF). Here, we develop an anti-fibrotic platform that can modulate both the lysophosphatidic acid receptor 1 (LPA 1 ) and the inflammatory pathway through tumor necrosis factor α -induced protein 3 (TNFAIP3, also known as A20) in fibroblasts. First, we synthesized a series of LPA 1 antagonists, AM095 and AM966, derived amino lipids (LA lipids) which were formulated into LA-lipid nanoparticles (LA-LNPs) encapsulating mRNA. Specifically, LA5-LNPs, with AM966 head group and biodegradable acetal lipid tails, showed efficient A20 mRNA delivery to lung fibroblasts in vitro (80.2% ± 1.5%) and ex vivo (17.2% ± 0.4%). When treated to primary mouse lung fibroblasts (MLF), this formulation inhibited fibroblast migration and collagen production, thereby slowing the progression of IPF. Overall, LA5-LNPs encapsulated with A20 mRNA is a novel platform offering a potential approach to regulate fibroblast activation for the treatment of IPF.

Schlagwörter

Stichwörter der Autor:innen

lipid nanoparticleslung fibrosislysophosphatidic acid receptor 1 (LPA1) antagonistmRNAtumor necrosis factor α-induced protein 3 (A20)

Autor:innen und Institutionen

  • Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
  • Icahn Genomics Institute, Precision Immunology Institute, Department of Immunology and Immunotherapy, Department of Oncological Sciences, Tisch Cancer Institute, Biomedical Engineering and Imaging Institute, Friedman Br…
  • Center for Electron Microscopy and Analysis, The Ohio State University, Columbus, OH 43212, USA.
  • Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA.

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Yan, J., Kang, D. D., Wang, C., Hou, X., Du, S., Wang, S., Xue, Y., Liu, Z., Li, H., Zhong, Y., Deng, B., McComb, D. W., & Dong, Y. (2024). LPA1 antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities. Nano Research, 17(10), 9095-9102. https://doi.org/10.1007/s12274-024-6747-6

Vancouver

Yan J, Kang DD, Wang C, Hou X, Du S, Wang S, et al. LPA1 antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities. Nano Research. 2024;17(10):9095-9102. doi:10.1007/s12274-024-6747-6

BibTeX
@article{Yan2024,
  author = {Yan, Jingyue and Kang, Diana D and Wang, Chang and Hou, Xucheng and Du, Shi and Wang, Siyu and Xue, Yonger and Liu, Zhengwei and Li, Haoyuan and Zhong, Yichen and Deng, Binbin and McComb, David W and Dong, Yizhou},
  title = {LPA1 antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities},
  journal = {Nano Research},
  year = {2024},
  volume = {17},
  number = {10},
  pages = {9095--9102},
  doi = {10.1007/s12274-024-6747-6}
}
Kostenlos starten →